🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

6,867 results for “De” Clear

  1. L-ornithine-L-aspartate

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Decompensated Cirrhosis

    phase 3 small molecule completed

    1 trial

  2. LAMIVUDINE AND DOLUTEGRAVIR , DARUNAVIR , DORAVIRINE , DARUNAVIR AND COBICISTAT , EMTRICITABINE, TENOFOVIR ALAFENAMIDE, DARUNAVIR AND COBICISTAT, TENOFOVIR ALAFENAMIDE , RITONAVIR , ISLATRAVIR/LENACAPAVIR, LAMIVUDINE, ABACAVIR AND DOLUTEGRAVIR, EMTRICITABINE, TENOFOVIR ALAFENAMIDE, ELVITEGRAVIR AND COBICISTAT, EMTRICITABINE, RALTEGRAVIR , EMTRICITABINE, TENOFOVIR ALAFENAMIDE AND BICTEGRAVIR, EMTRICITABINE, TENOFOVIR DISOPROXIL AND RILPIVIRINE, DOLUTEGRAVIR , LAMIVUDINE, TENOFOVIR DISOPROXIL AND DORAVIRINE,

    Gilead Sciences Pty Limited

    HIV-1 Infection

    phase 3 small molecule active

    1 trial

  3. LANREOTIDE, LANREOTIDE, Debio 4126, Debio 4126, Ready-to-use suspension resembling 30, 60, or 90 mg Debio 4126 doses, Debio 4126, OCTREOTIDE, OCTREOTIDE, LANREOTIDE, OCTREOTIDE

    Alphapharm Pty Ltd

    Acromegaly

    phase 3 small molecule active

    1 trial

  4. LDX 30 mg

    Takeda

    Attention Deficit Hyperactivity Disorder (ADHD)

    phase 3 small molecule completed

    1 trial

  5. LEDERFOLIN 25 mg Polvere per soluzione iniettabile per uso endovenoso, CYTARABINE, METHOTREXATE, CYTARABINE, PREDNISONE, METHOTREXATE, Melphalan 50 mg powder and solvent for solution for injection/infusion, METHYLPREDNISOLONE SODIUM SUCCINATE, Idarubicina Sandoz 1 mg/ml concentrato per soluzione per infusione, METHOTREXATE, PREDNISONE, FILGRASTIM, Glivec 100 mg hard capsules, CYTARABINE, PURINETHOL 50 mg compresse, Dexamethasone Phosphate 4 mg/ml Solution for Injection, Keppra 250 mg film-coated tablets, ME

    Fondazione Telethon ETS

    Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.

    phase 3 small molecule active

    1 trial

  6. LETROZOLE, ANASTROZOLE, CAPECITABINE, PACLITAXEL, CAPECITABINE, Verzenios 50 mg film-coated tablets, FULVESTRANT

    Ningbo Cancer Hospital

    Patients with untreated metastatic Estrogen Receptor positive (ER+), Human Epidermal Growth Factor Receptor-2 negative (HER2-) breast cancer with visceral involvement

    phase 3 small molecule active

    1 trial

  7. LETROZOLE, Arimidex® 1 mg Filmtabletten, Camizestrant, ABEMACICLIB, GOSERELIN, TRIPTORELIN, LEUPRORELIN ACETATE, Nolvadex® 20 mg Filmtabletten, EXEMESTANE

    AstraZeneca AB

    ER+/HER2- Early Breast Cancer

    phase 3 small molecule active

    1 trial

  8. LETROZOLE, DOCETAXEL, ANASTROZOLE, LEUPRORELIN ACETATE, LEUPRORELIN ACETATE, TAMOXIFEN, EPIRUBICIN, DOXORUBICIN, GOSERELIN, TRIPTORELIN, EXEMESTANE, PACLITAXEL, CYCLOPHOSPHAMIDE, GOSERELIN, TRIPTORELIN

    Ningbo Cancer Hospital

    Premenopausal patients with high-risk HR-positive/HER2-negative breast cancer (BC) defined by tumour size and axillary lymph node status. One of the following must apply: a. 1-3 lymph nodes involved AND any invasive tumour size. b. node negative (including micrometastases in at least 1 node [i.e. deposit >0.2-2mm diameter]) AND invasive tumour size ≥ 50mm.

    phase 3 small molecule active

    1 trial

  9. LETROZOLE, ELACESTRANT, ANASTROZOLE, EXEMESTANE, TAMOXIFEN, ELACESTRANT

    Stemline Therapeutics B.V.

    Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast Cancer with High Risk of Recurrence

    phase 3 small molecule active

    1 trial

  10. LETROZOLE, PALBOCICLIB, Inavolisib placebo, LETROZOLE ACCORD HEALTHCARE 2,5 mg, comprimé pelliculé, IBRANCE 75 mg film-coated tablets, IBRANCE 125 mg film-coated tablets, Letrozol STADA® 2,5 mg Filmtabletten, INAVOLISIB, IBRANCE 100 mg film-coated tablets, INAVOLISIB, RIBOCICLIB, PALBOCICLIB, RIBOCICLIB, PALBOCICLIB

    Hoffmann-La Roche

    Endocrine-Sensitive phosphatidylinositol 3-kinase (PIK3CA)-Mutated, Hormone Receptor-Positive, human epidermal growth factor receptor 2- (HER2-) negative advanced breast cancer

    phase 3 small molecule active

    1 trial

  11. LEUPRORELIN ACETATE, BAY 1841788, NUBEQA 300 mg film-coated tablets, TRIPTORELIN, DEGARELIX, GOSERELIN

    Ningbo Cancer Hospital

    Castrate-resistant prostate cancer with oligometastases on functional imaging (PSMA or choline/fluciclovine-positron-emission tomography).

    phase 3 small molecule active

    1 trial

  12. LGP PURE CBD 200, caprylic/capric triglyceride liquid

    The George Institute

    Patients with stage I, II, III hormone-receptor positive (HR+) breast cancer (BC) receiving adjuvant aromatase inhibitors (AI) and presenting AI-related musculoskeletal pain (reported average joint pain score of ≥ 4 out of 10 on the Brief Pain Inventory)

    phase 3 small molecule active

    1 trial

  13. LGP PURE CBD 200, caprylic/capric triglyceride liquid

    The George Institute

    Patients with stage I, II, III hormone-receptor positive (HR+) breast cancer (BC) receiving adjuvant aromatase inhibitors (AI) and presenting AI-related musculoskeletal pain (reported average joint pain score of ≥ 4 out of 10 on the Brief Pain Inventory)

    phase 3 small molecule active

    1 trial

  14. LIBTAYO 350 mg concentrate for solution for infusion., Armisarte 25 mg/ml concentrate for solution for infusion, Gemcitabine 2 g Powder for Solution for Infusion, Paclitaxel 6 mg/ml Concentrate for Solution for Infusion, Carboplatin 10 mg/ml concentrate for solution for infusion, Cisplatin 1 mg/ml Concentrate for Solution for Infusion

    Lacuna Pharma Pty Ltd

    Non-small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  15. LIBTAYO 350 mg concentrate for solution for infusion., Vinorelbine 10 mg/ml concentrate for solution for infusion, TAXOTERE 20 mg/0.5 ml concentrate and solvent for solution for infusion, THIO, Gemcitabine 1 g Powder for Solution for Infusion

    MAIA Biotechnology

    Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  16. LOPERAMIDE , Ultra-Levura 250 mg cápsulas duras, Placebo to Saccharomyces boulardii

    Biocodex

    Non-constipated Irritable Bowel Syndrome (IBS)

    phase 3 small molecule active

    1 trial

  17. LOU064 (blinded)

    Novartis Pharmaceuticals

    Chronic Spontaneous Urticaria

    phase 3 small molecule completed

    1 trial

  18. LOU064, CLINDAMYCIN , Placebo to remibrutinib (lou064) 0 mg matching 00 mg film-coated tablet, LOU064, Placebo to remibrutinib (lou064) 0 mg matching 00 mg film-coated tablet, TRIAMCINOLONE , -

    Novartis Pharmaceuticals

    Hidradenitis Suppurativa (HS)

    phase 3 small molecule active

    1 trial

  19. LOU064, COLESTYRAMINE , TERIFLUNOMIDE, Placebo to teriflunomide 14 mg capsule, hard, Placebo to Remibrutinib (LOU064) 100 mg film-coated tablet, MEDICINAL CHARCOAL

    Novartis Pharmaceuticals

    Multiple Sclerosis

    phase 3 small molecule active

    1 trial

  20. LOU064, Placebo to teriflunomide 14 mg capsule, hard, COLESTYRAMINE , Placebo to Remibrutinib (LOU064) 100 mg film-coated tablet, TERIFLUNOMIDE, MEDICINAL CHARCOAL

    Novartis Pharmaceuticals

    Multiple Sclerosis

    phase 3 small molecule active

    1 trial

  21. LP352 (bexicaserin) Placebo Oral Solution, Bexicaserin

    Lacuna Pharma Pty Ltd

    Developmental and Epileptic Encephalopathies (DEE)

    phase 3 small molecule active

    1 trial

  22. LP352 (bexicaserin) Placebo Oral Solution, Bexicaserin

    Lacuna Pharma Pty Ltd

    Developmental and Epileptic Encephalopathies (DEEs)

    phase 3 small molecule active

    1 trial

  23. LV305

    Lxo Ireland Designated Activity Company

    Synovial Sarcoma

    phase 3 mab terminated

    1 trial

  24. LY2216684

    Eli Lilly and Company

    Major Depressive Disorder

    phase 3 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources